PHAR logo

Pharming Group NV (PHAR) Accounts Receivable

Annual Accounts Receivable

$35.41 M
+$14.44 M+68.90%

31 December 2023

PHAR Accounts Receivable Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly Accounts Receivable

$48.20 M
-$2.92 M-5.71%

30 September 2024

PHAR Quarterly Accounts Receivable Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PHAR Accounts Receivable Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+68.9%+18.9%
3 y3 years+50.6%+46.9%
5 y5 years+101.8%+63.3%

PHAR Accounts Receivable High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3 yearsat high+95.9%-5.7%+166.7%
5 y5 yearsat high+101.8%-5.7%+166.7%
alltimeall timeat high-5.7%

Pharming Group NV Accounts Receivable History

DateAnnualQuarterly
Sept 2024
-
$48.20 M(-5.7%)
June 2024
-
$51.12 M(+32.1%)
Mar 2024
-
$38.70 M(+9.3%)
Dec 2023
$35.41 M(+68.9%)
$35.41 M(-12.6%)
Sept 2023
-
$40.52 M(+22.2%)
June 2023
-
$33.16 M(+0.7%)
Mar 2023
-
$32.93 M(+57.1%)
Dec 2022
$20.96 M(+16.0%)
$20.96 M(-27.3%)
Sept 2022
-
$28.83 M(-12.3%)
June 2022
-
$32.88 M(+4.6%)
Mar 2022
-
$31.45 M(+74.0%)
Dec 2021
$18.08 M(-23.1%)
$18.08 M(-44.9%)
Sept 2021
-
$32.81 M(-12.7%)
June 2021
-
$37.57 M(+14.2%)
Mar 2021
-
$32.88 M(+39.8%)
Dec 2020
$23.51 M(-18.5%)
$23.51 M(-24.3%)
Sept 2020
-
$31.05 M(+4.6%)
June 2020
-
$29.68 M(-12.0%)
Mar 2020
-
$33.71 M(+16.8%)
Dec 2019
$28.86 M(+64.5%)
$28.86 M(-2.2%)
Sept 2019
-
$29.52 M(+5.5%)
June 2019
-
$28.00 M(+9.4%)
Mar 2019
-
$25.59 M(+45.9%)
Dec 2018
$17.54 M(+64.4%)
$17.54 M(-36.0%)
Sept 2018
-
$27.39 M(+41.2%)
June 2018
-
$19.40 M(+9.5%)
Mar 2018
-
$17.72 M(+66.0%)
Dec 2017
$10.67 M
$10.67 M(-47.4%)
DateAnnualQuarterly
Sept 2017
-
$20.28 M(-4.9%)
June 2017
-
$21.33 M(+0.6%)
Mar 2017
-
$21.21 M(+221.1%)
Dec 2016
$6.60 M(+186.8%)
$6.60 M(+0.3%)
Sept 2016
-
$6.59 M(+6.7%)
June 2016
-
$6.17 M(+40.5%)
Mar 2016
-
$4.39 M(+90.8%)
Dec 2015
$2.30 M(+170.1%)
$2.30 M(-50.5%)
Sept 2015
-
$4.65 M(-2.6%)
June 2015
-
$4.77 M(+85.7%)
Mar 2015
-
$2.57 M(+201.6%)
Dec 2014
$852.40 K(+192.5%)
$852.40 K(-59.7%)
Sept 2014
-
$2.12 M(+19.2%)
June 2014
-
$1.77 M(+119.9%)
Mar 2014
-
$807.30 K(+177.0%)
Dec 2013
$291.40 K(>+9900.0%)
$291.40 K(-51.9%)
Sept 2013
-
$605.90 K(-91.4%)
June 2013
-
$7.09 M(+724.5%)
Mar 2013
-
$859.30 K(>+9900.0%)
Dec 2012
$0.00(-100.0%)
$0.00(-100.0%)
Sept 2012
-
$1.27 M(-18.0%)
Mar 2012
-
$1.55 M(+238.5%)
Dec 2011
$457.50 K(-96.5%)
$457.50 K(-63.3%)
Sept 2011
-
$1.25 M(+26.1%)
June 2011
-
$990.20 K(+20.1%)
Mar 2011
-
$824.60 K(-93.8%)
Dec 2010
$13.21 M(+562.3%)
$13.21 M(+562.3%)
Dec 2009
$1.99 M
$1.99 M

FAQ

  • What is Pharming Group NV annual accounts receivable?
  • What is the all time high annual accounts receivable for Pharming Group NV?
  • What is Pharming Group NV annual accounts receivable year-on-year change?
  • What is Pharming Group NV quarterly accounts receivable?
  • What is the all time high quarterly accounts receivable for Pharming Group NV?
  • What is Pharming Group NV quarterly accounts receivable year-on-year change?

What is Pharming Group NV annual accounts receivable?

The current annual accounts receivable of PHAR is $35.41 M

What is the all time high annual accounts receivable for Pharming Group NV?

Pharming Group NV all-time high annual accounts receivable is $35.41 M

What is Pharming Group NV annual accounts receivable year-on-year change?

Over the past year, PHAR annual accounts receivable has changed by +$14.44 M (+68.90%)

What is Pharming Group NV quarterly accounts receivable?

The current quarterly accounts receivable of PHAR is $48.20 M

What is the all time high quarterly accounts receivable for Pharming Group NV?

Pharming Group NV all-time high quarterly accounts receivable is $51.12 M

What is Pharming Group NV quarterly accounts receivable year-on-year change?

Over the past year, PHAR quarterly accounts receivable has changed by +$7.68 M (+18.95%)